DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) (NCT05566795)
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
🩺 Plain-English Summary (8th-Grade Level)
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Who can join: Review the eligibility criteria below.
Location: Children's of Alabama — Birmingham, Alabama
Age range: Not specified to 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (138 Sites)
Showing the first 25 of 138 sites.
- Children's of Alabama — Birmingham, Alabama
- Phoenix Children's Hospital — Phoenix, Arizona
- Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County Main Campus - Orange — Orange, California
- Packard Children's Hospital Stanford — Palo Alto, California
- UCSF Benioff Children's Hospital — San Francisco, California
- Children's Hospital Colorado — Aurora, Colorado
- Connecticut Children's Medical Center — Hartford, Connecticut
- Children's National Medical Center — Washington D.C., District of Columbia
- University of Florida Health — Gainesville, Florida
- Nicklaus Children's Hospital — Miami, Florida
- Arnold Palmer Hospital for Children — Orlando, Florida
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida
- Children's Healthcare of Atlanta — Atlanta, Georgia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Riley Hospital for Children at Indiana University Health — Indianapolis, Indiana
- University of Iowa Hospitals Clinics — Iowa City, Iowa
- Norton Children's Hospital — Louisville, Kentucky
- Maine Children's Cancer Program — Scarborough, Maine
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan - - C.S. Mott Children's Hospital — Ann Arbor, Michigan
- Children's Minnesota — Minneapolis, Minnesota
- Childrens MS Cncr Ctr Bld Dsr — Jackson, Mississippi
- St. Louis Children's Hospital — St Louis, Missouri
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Low-grade Glioma
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. — Calgary, Alberta
- Niraparib In Recurrent IDH 1/2 Gliomas — Boston, Massachusetts
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma — Memphis, Tennessee
- CEST in Low-grade Glioma Study — Toronto, Ontario
- Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas — Toronto, Ontario
Explore by condition: All Low-grade Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.